DSIP vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide
DSIP, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s from the blood of sleeping rabbits. As the name suggests, it was named for its ability to promote delta-wave (deep, slow-wave) sleep in animals. Despite five decades of study it has no regulatory approval and the human evidence for it as a sleep aid is weak and inconsistent.
Also: Elamipretide, Bendavia
SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2), known generically as elamipretide and sold as FORZINITY, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. It works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more ATP with less oxidative damage. This is the rare research peptide with a real regulatory finish line: the FDA granted it accelerated approval in September 2025 for Barth syndrome, though it has failed several other major trials.
Key Comparison Insights
- SS-31 is FDA approved, while DSIP remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to DSIP (Human Trials).
Detailed Comparison
| Attribute | DSIP | SS-31 |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | How DSIP actually works is still not nailed down, which is unusual for a peptide this old. It does not have one clear receptor of its own. Instead it seems to act as a modulator, influencing slow-wave sleep, neurotransmitter levels, circadian rhythm, hormone release (including growth hormone), and stress responses. One striking animal finding: injecting antibodies against DSIP into the brain blocked the normal rise in slow-wave sleep and growth hormone, hinting that the body's own DSIP plays a real regulatory role. Some reports also suggest it can act on opioid-related pathways, which is why it has been studied in addiction withdrawal. Treat these mechanisms as plausible but not fully proven. | SS-31 is a cell-permeable, mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds tightly to cardiolipin. Cardiolipin is essential for keeping the membrane's folded cristae structure intact and for organizing the proteins of the electron transport chain that generate ATP. By stabilizing cardiolipin, SS-31 helps preserve cristae shape, reduces the electron leakage that produces reactive oxygen species, and supports more efficient ATP production. Studies also suggest it modulates the membrane's surface electrostatics and can limit opening of the mitochondrial permeability transition pore, a trigger for cell death, though the full mechanistic picture is still being worked out. |
| Common Dosing | 100-250 mcg before bed Once daily, 30 min before sleep | 40 mg subcutaneous daily Once daily |
| Administration | Subcutaneous, intramuscular, or intranasal | Subcutaneous injection or IV infusion |
| Typical Duration | 2-4 weeks typical | Variable by condition |
| Best Time to Take | 30-60 minutes before bed | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The early animal work was genuinely interesting: DSIP reliably increased delta sleep in rabbits, rats, and mice, and seemed tied to growth hormone release during sleep. The human data is far less convincing. A few small studies reported longer or better sleep after intravenous DSIP in chronic insomniacs, with no daytime grogginess. But a double-blind, placebo-controlled study published in Neuropsychobiology (1992) concluded that short-term DSIP treatment of chronic insomnia is unlikely to be of major therapeutic benefit, since objective gains were weak and patients did not feel their sleep was better. Separate older reports claimed high success rates relieving opiate and alcohol withdrawal symptoms, but these were small, uncontrolled, and never replicated to modern standards. Bottom line: real history, real animal data, but no solid randomized evidence that it works as a sleep drug in people. | Unlike most peptides in this space, SS-31 has been through extensive human trials, with a mixed but consequential record. In TAZPOWER, a randomized placebo-controlled crossover study in Barth syndrome, elamipretide improved skeletal muscle strength and cardiac stroke volume, and the long open-label extension showed sustained benefit, which ultimately supported FDA accelerated approval in September 2025 as the first treatment for that ultra-rare disease. It has also failed prominently: the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints on the six-minute walk test, the ReCLAIM trial in dry age-related macular degeneration did not hit its primary endpoints, and a heart-failure trial (PROGRESS-HF) also missed its primary endpoint. Across these studies the drug was generally well tolerated, with mostly mild effects such as injection-site reactions, headache and nausea. The accurate summary is that SS-31 is a validated mitochondrial-targeting peptide with one approved indication and a string of negative trials elsewhere, so its benefit appears to depend heavily on the specific disease. |
Frequently Asked Questions: DSIP vs SS-31
What is the difference between DSIP and SS-31?
DSIP is a anti-aging peptide that dsip, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide (sequence trp-ala-gly-gly-asp-ala-ser-gly-glu) first isolated in the 1970s from the blood of sleeping rabbits. as the name suggests, it was named for its ability to promote delta-wave (deep, slow-wave) sleep in animals. despite five decades of study it has no regulatory approval and the human evidence for it as a sleep aid is weak and inconsistent. SS-31 is a anti-aging peptide that ss-31 (sequence d-arg-dmt-lys-phe-nh2), known generically as elamipretide and sold as forzinity, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. it works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more atp with less oxidative damage. this is the rare research peptide with a real regulatory finish line: the fda granted it accelerated approval in september 2025 for barth syndrome, though it has failed several other major trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, DSIP or SS-31?
Neither is universally "better" - the choice depends on your specific goals. DSIP is typically used for anti-aging purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can DSIP and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using DSIP and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.